Literature DB >> 29935887

A positive take on schizophrenia negative symptom scales: Converting scores between the SANS, NSA and SDS.

Adrian Preda1, Dana D Nguyen2, Juan R Bustillo3, Aysenil Belger4, Daniel S O'Leary5, Sarah McEwen6, Shichun Ling7, Lawrence Faziola7, Daniel H Mathalon8, Judith M Ford9, Steven G Potkin7, Theo G M van Erp10.   

Abstract

AIMS: To provide quantitative conversions between commonly used scales for the assessment of negative symptoms in schizophrenia.
METHOD: Linear regression analyses generated conversion equations between symptom scores from the Scale for the Assessment of Negative Symptoms (SANS), the Schedule for the Deficit Syndrome (SDS), the Positive and Negative Syndrome Scale (PANSS), or the Negative Symptoms Assessment (NSA) based on a cross sectional sample of 176 individuals with schizophrenia. Intraclass correlations assessed the rating conversion accuracy based on a separate sub-sample of 29 patients who took part in the initial study as well as an independent sample of 28 additional subjects with schizophrenia.
RESULTS: Between-scale negative symptom ratings were moderately to highly correlated (r = 0.73-0.91). Intraclass correlations between the original negative symptom rating scores and those obtained via using the conversion equations were in the range of 0.61-0.79.
CONCLUSIONS: While there is a degree of non-overlap, several negative symptoms scores reflect measures of similar constructs and may be reliably converted between some scales. The conversion equations are provided at http://www.converteasy.org and may be used for meta- and mega-analyses that examine negative symptoms.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Conversion; Meta-; Multi-center; Multi-site; NSA; Negative symptoms; PANSS; SANS; SDA; Schizophrenia

Mesh:

Year:  2018        PMID: 29935887      PMCID: PMC7039318          DOI: 10.1016/j.schres.2018.06.014

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  21 in total

Review 1.  Can we combine symptom scales for collaborative research projects?

Authors:  John P Lyne; Anthony Kinsella; Brian O'Donoghue
Journal:  J Psychiatr Res       Date:  2011-11-05       Impact factor: 4.791

2.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

Review 3.  Issues in selection of instruments to measure negative symptoms.

Authors:  David Gordon Daniel
Journal:  Schizophr Res       Date:  2013-07-27       Impact factor: 4.939

4.  A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS.

Authors:  R M Norman; A K Malla; L Cortese; F Diaz
Journal:  Schizophr Res       Date:  1996-03       Impact factor: 4.939

5.  Converting positive and negative symptom scores between PANSS and SAPS/SANS.

Authors:  Theo G M van Erp; Adrian Preda; Dana Nguyen; Lawrence Faziola; Jessica Turner; Juan Bustillo; Aysenil Belger; Kelvin O Lim; Sarah McEwen; James Voyvodic; Daniel H Mathalon; Judith Ford; Steven G Potkin
Journal:  Schizophr Res       Date:  2013-12-11       Impact factor: 4.939

6.  The Schedule for the Deficit syndrome: an instrument for research in schizophrenia.

Authors:  B Kirkpatrick; R W Buchanan; P D McKenney; L D Alphs; W T Carpenter
Journal:  Psychiatry Res       Date:  1989-11       Impact factor: 3.222

7.  Assessment of negative symptoms and depression in schizophrenia: revision of the SANS and how it relates to the PANSS and CDSS.

Authors:  Liron Rabany; Mark Weiser; Nomi Werbeloff; Yechiel Levkovitz
Journal:  Schizophr Res       Date:  2010-11-05       Impact factor: 4.939

8.  The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

Authors:  S R Marder; J M Davis; G Chouinard
Journal:  J Clin Psychiatry       Date:  1997-12       Impact factor: 4.384

9.  Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis.

Authors:  Joseph Ventura; Gerhard S Hellemann; April D Thames; Vanessa Koellner; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2009-07-22       Impact factor: 4.939

10.  Clinical trials for negative symptoms--emerging directions and unresolved issues.

Authors:  Stephen R Marder; Jonathan Rabinowitz; Shitij Kapur
Journal:  Schizophr Res       Date:  2013-11       Impact factor: 4.939

View more
  2 in total

1.  EPA guidance on assessment of negative symptoms in schizophrenia.

Authors:  S Galderisi; A Mucci; S Dollfus; M Nordentoft; P Falkai; S Kaiser; G M Giordano; A Vandevelde; M Ø Nielsen; L B Glenthøj; M Sabé; P Pezzella; I Bitter; W Gaebel
Journal:  Eur Psychiatry       Date:  2021-02-18       Impact factor: 5.361

2.  Effects of a Short Emotional Management Program on Inpatients with Schizophrenia: A Pilot Study.

Authors:  Kyung-Hwan Park; Eun-Sook Park; Sung-Mi Jo; Mi-Hui Seo; Young-Ok Song; Sun-Joo Jang
Journal:  Int J Environ Res Public Health       Date:  2021-05-20       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.